B7-H4, a promising target for immunotherapy

Wang, Jiayu; Wang, Weipeng

doi:10.1016/j.cellimm.2019.104008

Cited by 71 publications

(54 citation statements)

References 133 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Once B7-H4 binds the T cells, it triggers a strong inhibitor effect on cell proliferation, interleukin secretion, as well as cytotoxicity activity [166] [167,168]. B7-H4 has also been reported to play a relevant role in cancer development and progression by inhibiting apoptosis and accelerating the proliferation, migration and invasion of the cells [169]. Zhen-Ye Li et al [170], evaluated B7-H4 expression in brain metastases from NSCLC, reporting that patients whose metastases were strongly positive for B7-H4 expression had a shorter median OS compared to patients with low expression of B7-H4 (11.4 months vs. 26.2 months; p = 0.002) [170].…”

Section: B7-h4mentioning

confidence: 99%

Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient

Rossi

Russo

Tagliamento

et al. 2020

Cancers

View full text Add to dashboard Cite

In recent years, the evolution of treatments has made it possible to significantly improve the outcomes of patients with non-small cell lung cancer (NSCLC). In particular, while molecular targeted therapies are effective in specific patient sub-groups, immune checkpoint inhibitors (ICIs) have greatly influenced the outcomes of a large proportion of NSCLC patients. While nivolumab activity was initially assessed irrespective of predictive biomarkers, subsequent pivotal studies involving other PD-1/PD-L1 inhibitors in pre-treated advanced NSCLC (atezolizumab within the OAK study and pembrolizumab in the Keynote 010 study) reported the first correlations between clinical outcomes and PD-L1 expression. However, PD-L1 could not be sufficient on its own to select patients who may benefit from immunotherapy. Many studies have tried to discover more precise markers that are derived from tumor tissue or from peripheral blood. This review aims to analyze any characteristics of the immunogram that could be used as a predictive biomarker for response to ICIs. Furthermore, we describe the most important genetic alteration that might predict the activity of immunotherapy.

show abstract

Section: B7-h4mentioning

confidence: 99%

Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient

Rossi

Russo

Tagliamento

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…B7-H4 is a coinhibitory molecule contributing to the B7 family [ 214 , 215 ]. It binds to unknown receptors on activated T cells [ 216 ] and transmits negative immuno-modulatory signals, thus promoting immune escape through negative regulations of cytokine secretion, cell proliferation, and the T cell cycle [ 217 ]. B7-H4 is highly expressed on tumor-associated macrophages [ 218 ] and in many solid tumors, such as OC, BC, lung cancer, renal cell cancer, and pancreatic cancer [ 219 – 224 ].…”

Section: Introductionmentioning

confidence: 99%

Immunotherapy in endometrial cancer: rationale, practice and perspectives

Cao

Fischer

et al. 2021

Biomark Res

View full text Add to dashboard Cite

Tumor immunotherapy has attracted more and more attention nowadays, and multiple clinical trials have confirmed its effect in a variety of solid tumors. Immune checkpoint inhibitors (ICIs), cancer vaccines, adoptive cell transfer (ACT), and lymphocyte-promoting cytokines are the main immunotherapy methods. Endometrial cancer (EC) is one of the most frequent tumors in women and the prognosis of recurrent or metastatic EC is poor. Since molecular classification has been applied to EC, immunotherapy for different EC subtypes (especially POLE and MSI-H) has gradually attracted attention. In this review, we focus on the expression and molecular basis of the main biomarkers in the immunotherapy of EC firstly, as well as their clinical application significance and limitations. Blocking tumor immune checkpoints is one of the most effective strategies for cancer treatment in recent years, and has now become the focus in the field of tumor research and treatment. We summarized clinical date of planned and ongoing clinical trials and introduced other common immunotherapy methods in EC, such as cancer vaccine and ACT. Hormone aberrations, metabolic syndrome (MetS) and p53 mutant and that affect the immunotherapy of endometrial cancer will also be discussed in this review.

show abstract

“…It has been shown that CD8 + T cells, natural killer cells, and dendritic cells are cytotoxic to ovarian cancer 38 . TGFβR1, 44 IDO1, VTCN1, 45 and CD160 46 are involved in tumor immune escape and are effective targets for tumor immunotherapy. Among these, IDO1 is highly expressed in most types of cancer and is associated with the poor prognosis of patients 47 .…”

Section: Discussionmentioning

confidence: 99%

MRPL15 is a novel prognostic biomarker and therapeutic target for epithelial ovarian cancer

Zou

et al. 2021

Cancer Medicine

View full text Add to dashboard Cite

PurposeTo analyze the role of six human epididymis protein 4 (HE4)‐related mitochondrial ribosomal proteins (MRPs) in ovarian cancer and selected MRPL15, which is most closely related to the tumorigenesis and prognosis of ovarian cancer, for further analyses.MethodsUsing STRING database and MCODE plugin in Cytoscape, six MRPs were identified among genes that are upregulated in response to HE4 overexpression in epithelial ovarian cancer cells. The Cancer Genome Atlas (TCGA) ovarian cancer, GTEX, Oncomine, and TISIDB were used to analyze the expression of the six MRPs. The prognostic impact and genetic variation of these six MRPs in ovarian cancer were evaluated using Kaplan‐Meier Plotter and cBioPortal, respectively. MRPL15 was selected for immunohistochemistry and GEO verification. TCGA ovarian cancer data, gene set enrichment analysis, and Enrichr were used to explore the mechanism of MRPL15 in ovarian cancer. Finally, the relationship between MRPL15 expression and immune subtype, tumor‐infiltrating lymphocytes, and immune regulatory factors was analyzed using TCGA ovarian cancer data and TISIDB.ResultsSix MRPs (MRPL10, MRPL15, MRPL36, MRPL39, MRPS16, and MRPS31) related to HE4 in ovarian cancer were selected. MRPL15 was highly expressed and amplified in ovarian cancer and was related to the poor prognosis of patients. Mechanism analysis indicated that MRPL15 plays a role in ovarian cancer through pathways such as the cell cycle, DNA repair, and mTOR 1 signaling. High expression of MRPL15 in ovarian cancer may be associated with its amplification and hypomethylation. Additionally, MRPL15 showed the lowest expression in C3 ovarian cancer and was correlated with proliferation of CD8+ T cells and dendritic cells as well as TGFβR1 and IDO1 expression.ConclusionMRPL15 may be a prognostic indicator and therapeutic target for ovarian cancer. Because of its close correlation with HE4, this study provides insights into the mechanism of HE4 in ovarian cancer.

show abstract

B7-H4, a promising target for immunotherapy

Cited by 71 publications

References 133 publications

Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient

Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient

Immunotherapy in endometrial cancer: rationale, practice and perspectives

MRPL15 is a novel prognostic biomarker and therapeutic target for epithelial ovarian cancer

Contact Info

Product

Resources

About